Proxai

ProxAl is a pioneering Quebec-based techbio startup, delivering an exclusive and integrated platform that fundamentally accelerates the design and validation of novel therapeutics. Building on the recent, transformative advancements in deep learning for rational protein design, we are now enabling the development of groundbreaking therapies for previously 'hard-to-drug' diseases. The platform's adaptability and integrated design capabilities make it highly versatile, allowing for the rapid creation of novel therapeutics across diverse disease categories. Our proprietary technology seamlessly combines de novo artificial intelligence (AI) protein design with a unique high-throughput cellular screening system. This powerful synergy allows us to aggressively pursue high-value disease pathways with unmet medical needs, discovering breakthrough drug candidates, especially those intractable to traditional small molecule approaches.